Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 36,312 | 1,647 | -329,668 | -294,317 | -241,484 |
| Depreciation Amortization | 15,364 | 179,711 | 552,483 | 387,863 | 220,286 |
| Income taxes - deferred | -82,315 | -45,339 | 69,198 | 96,593 | 171,587 |
| Accounts receivable | -34,231 | -9,723 | -92,735 | -27,956 | -34,838 |
| Accounts payable and accrued liabilities | -24,771 | -27,617 | 57,021 | 19,167 | 19,309 |
| Other Working Capital | -118,635 | -40,690 | -47,952 | 36,968 | -22,071 |
| Other Operating Activity | 720,291 | 150,990 | 570,160 | 382,434 | 213,903 |
| Operating Cash Flow | $512,015 | $208,979 | $778,507 | $600,752 | $326,692 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -60,736 | N/A | 1,068,181 | 1,068,306 | 1,068,900 |
| PPE Investments | -24,570 | -12,292 | -27,641 | -17,674 | -9,346 |
| Net Acquisitions | 53,000 | N/A | -6,234,792 | -6,234,792 | -6,234,792 |
| Purchase Sale Intangibles | -94,148 | -25,000 | -17,891 | -17,891 | 0 |
| Other Investing Activity | -94,148 | -25,000 | -17,891 | -17,891 | 0 |
| Investing Cash Flow | $-126,454 | $-37,292 | $-5,212,143 | $-5,202,051 | $-5,175,238 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 5,191,463 | 5,191,463 | 5,191,463 |
| Debt Repayment | -266,518 | -258,764 | -1,320,600 | -1,061,840 | -584,268 |
| Common Stock Issued | 46,603 | 21,729 | 135,261 | 117,111 | 102,289 |
| Common Stock Repurchased | -54 | N/A | N/A | N/A | 0 |
| Other Financing Activity | -40,065 | -33,776 | -35,602 | -29,603 | -27,172 |
| Financing Cash Flow | $-260,034 | $-270,811 | $3,970,522 | $4,217,131 | $4,682,312 |
| Exchange Rate Effect | -5,710 | -1,489 | -3,207 | -1,821 | -135 |
| Beginning Cash Position | 591,448 | 591,448 | 1,057,769 | 1,057,769 | 1,057,769 |
| End Cash Position | 711,265 | 490,835 | 591,448 | 671,780 | 891,400 |
| Net Cash Flow | $119,817 | $-100,613 | $-466,321 | $-385,989 | $-166,369 |
| Free Cash Flow | |||||
| Operating Cash Flow | 512,015 | 208,979 | 778,507 | 600,752 | 326,692 |
| Capital Expenditure | -24,570 | -12,292 | -27,641 | -17,674 | -9,346 |
| Free Cash Flow | 487,445 | 196,687 | 750,866 | 583,078 | 317,346 |